The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
AIBD 2010: Strategies for Managing Loss of Response in IBD Treatment
When IBD patients experience loss of response to therapy, the decision to escalate the dose or switch to other drugs depends on a number of factors.
AIBD 2010: Controversies in IBD: Mucosal Healing vs. Symptom Control
What is the proper balance between mucosal healing and symptom control in treating patients with IBD?
AIBD 2010: What Measure Should Be Used to Assess IBD Outcomes?
Symptoms, not mucosal healing, should be the endpoint used in clinical practice to assess outcomes of patients with inflammatory bowel disease.
AIBD 2010: Promising New Biologics in Development to Treat IBD
Novel biologics in development may provide alternatives to current standards of care in treating patients with refractory inflammatory bowel disease.
AIBD 2010: IBD Treatment Associated with Rare but Serious Complications
Adverse complications associated with IBD treatment may be uncommon, but awareness of these potential side effects is essential for proper management.
AIBD 2010: Will More Uniform Quality of Care Improve IBD Outcomes?
Defining, measuring, and tracking the care gastroenterologists provide to patients with IBD will improve the quality and consistency of care.
AIBD 2010: Only a Minority of At-risk IBD Patients Are Immunized
Most at-risk IBD patients have not received recommended vaccinations, even though 80% of these patients have visited their doctor in the last year.
AIBD 2010: Lessons Learned in the Treatment of Pediatric and Adult IBD
Lessons learned in the management of children with IBD may help gastroenterologists improve the diagnosis and management of adults with the condition.
Information for Attendees of the 2010 AIBD Conference
Scheduling, registration, and other information for attendees of the 2010 Advances in Inflammatory Bowel Diseases, Clinical & Research Conference.
ASN 2010: Insight into the Management of Intradialytic Hypertension
Overlapping clinical definitions of the causes and characteristics of intradialytic hypertension make it a frustrating condition to diagnose and treat
ASN 2010: Gene Variant May Explain High ESRD Rate in African Americans
AASK trial data show mutation in MYH9 gene significantly increases risk of ESRD in African Americans with kidney disease related to hypertension.
ASN 2010: Should JNC 7 Guidelines Be Used in Dialysis Patients?
Prominent cardiologist has some blunt advice for clinicians who are trying to apply JNC 7 guidelines in patients with CKD.
ASN 2010: Risk of Atrial Fibrillation and Other CVD in CKD Patients
CKD stage is a predictor of incident AF and mortality risk in elderly patients. Patients with CKD also frequently exhibit major EKG abnormalities.
ASN 2010: Peginesatide Associated with Increased Risk of CV Events
Peginesatide as effective as standard treatment for anemia in patients with kidney disease, but with higher risk for angina and arrhythmia.
ASN 2010: Lowering LDL in CKD Patients Reduces Risk of CV Events
SHARP trial shows that combination statin therapy in patients with CKD reduces risk of heart attack and stroke without raising cancer risk.
ASN 2010: New Treatment May Reverse the Progression of CKD
By targeting a novel inflammatory pathway, bardoxolone methyl can reduce the stage of chronic kidney disease and improve estimated glomerular filtration rate.
ASN 2010: Race, Poverty Linked to High Kidney Transplant Failure Rates
African Americans living in the poorest neighborhoods have double the risk of kidney transplant failure compared with white non-Hispanic patients.
ASN 2010: Hyponatremia and Risk of Falls and Fractures in the Elderly
Older adults with hyponatremia experience increased rates of fractures and falls, but are not at higher risk for osteoporosis.
ASN 2010: Recent Studies Paint a More Complete Picture of Hyponatremia
Combo therapy with thiazide diuretics may be a major cause of symptomatic hyponatremia, especially in older females with prior cerebrovascular events.
ASN 2010: Tolvaptan Effective on Dilutional Hyponatremia, Neuro Function
Studies show tolvaptan treats significant dilutional hyponatremia and can improve patient performance in neurocognitive and gait tests.
ASN 2010: The DASH Diet, Cardiovascular Health, and Patients with CKD
Researchers continue to study the cardiovascular benefits associated with the DASH diet. Patients with CKD should adjust potassium intake.
ASN 2010: Early Nephrologist Care Reduces Risk of ESRD in CKD Patients
Patients with chronic kidney disease treated by a nephrologist earlier in the care process face decreased risk of end-stage renal disease and death.
ASN 2010: CKD May Progress Faster in African Americans and Hispanics
Study showing racial differences in rate of kidney function decline may point to new opportunities for kidney disease prevention.
ASN 2010: Hyponatremia Treatment in the Spotlight at Renal Week
Information on diagnostic and therapeutic approaches to hyponatremia, including tolvaptan and other VRAs, will be presented at this year's conference.
ASN 2010: How Can We Reduce Racial Disparities in CKD and Diabetes?
Evidence-based strategies can alleviate gaps in providers' knowledge of chronic kidney disease and diabetes in underserved patient populations.
AHA 2010: Study Results Show Statins Do Not Increase Cancer Risk
Retrospective analysis reveals that statin use is not associated with increased risk of cancer.
AHA 2010: PTSD Linked to Increased Risk of CVD, Death in Veterans
Post-traumatic stress disorder more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease.
AHA 2010: How Can You Get Your Patients to Take Their Meds?
Poor medication plan adherence poses major health risks in patients with cardiovascular illnesses. Better adherence starts with better communication.
AHA 2010: CETP-inhibitor Anacetrapib has Dramatic Effects on HDL, LDL
Study shows that cholesteryl ester transfer protein (CETP) inhibitor anacetrapib reduced LDL by 40% and doubled HDL in patients with coronary disease.
AHA 2010: No Benefit from Larger Dose of Clopidogrel after PCI
GRAVITAS trial results show that high-dose clopidogrel does not reduce the incidence of death, heart attack, or blood clots in high-risk patients.